DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Household
Author Program NEWCreate Narrative
BHST logo

BioHarvest Sciences Inc. Stock Price

NasdaqGM:BHST Community·US$40.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

BHST Share Price Performance

US$1.87
-5.46 (-74.49%)
​
US$10.50
Fair Value
US$1.87
-5.46 (-74.49%)
82.2% undervalued intrinsic discount
US$10.50
Fair Value
Price US$1.87
AnalystConsensusTarget US$10.50
AnalystHighTarget US$15.00
AnalystLowTarget US$5.00
Wed, 26 Aug 26
Fair ValueUS$10.50
Share Pricen/a

BHST Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$10.5 82.2% undervalued intrinsic discount

Plant Based CDMO Expansion And Health Pros Network Will Drive Long Term Upside

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$15 87.5% undervalued intrinsic discount

CDMO Pipeline And Hydration Expansion Will Transform Long Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$5 62.6% undervalued intrinsic discount

CDMO Pipeline And Capacity Expansion Will Face Setbacks Yet Ultimately Support Future Earnings

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
BHST logo
BioHarvest Sciences
82.2% undervalued intrinsic discount

Plant Based CDMO Expansion And Health Pros Network Will Drive Long Term Upside

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 26 Aug
Read Narrative
BHST logo
BioHarvest Sciences
62.6% undervalued intrinsic discount

CDMO Pipeline And Capacity Expansion Will Face Setbacks Yet Ultimately Support Future Earnings

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 12 Aug
Read Narrative
BHST logo
BioHarvest Sciences
87.5% undervalued intrinsic discount

CDMO Pipeline And Hydration Expansion Will Transform Long Term Earnings Power

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 20 Feb
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
BHST logo

BHST: CDMO Contract Shift Will Drive Long-Term Revenue From 2027

Fair Value: US$10.5 82.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
BHST logo

BHST: Data Science Grant Will Support Future R&D Productivity Upside

Fair Value: US$5 62.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
BHST logo

CDMO Pipeline And Hydration Expansion Will Transform Long Term Earnings Power

Fair Value: US$15 87.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

High growth potential with adequate balance sheet.

2 Risks
2 Rewards
View Full Analysis

BioHarvest Sciences Inc. Key Details

US$35.5m

Revenue

US$14.6m

Cost of Revenue

US$20.9m

Gross Profit

US$32.0m

Other Expenses

-US$11.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.49
58.95%
-31.21%
13.5%
View Full Analysis

About BHST

Founded
n/a
Employees
89
CEO
Zaki Rakib
WebsiteView website
www.bioharvest.com

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.

Recent BHST News & Updates

User avatar
Narrative Update • Aug 26

BHST: CDMO Contract Shift Will Drive Long-Term Revenue From 2027

Analysts have reduced their fair value estimate for BioHarvest Sciences from $13.67 to $10.50. Recent research cites lower price targets tied to Q2 revenue shortfalls, reduced near-term guidance, and a shift in focus toward CDMO contracts that are expected to contribute more meaningfully from 2027.
Analysis Article • Aug 14

BioHarvest Sciences Inc. (NASDAQ:BHST) Just Reported And Analysts Have Been Cutting Their Estimates

BioHarvest Sciences Inc. ( NASDAQ:BHST ) missed earnings with its latest second-quarter results, disappointing...

Recent updates

No updates

BioHarvest Sciences Inc. Competitors

SKIN logo

SkinHealth Systems

Symbol: NasdaqCM:SKIN
Market cap: US$89.8m
FTLF logo

FitLife Brands

Symbol: NasdaqCM:FTLF
Market cap: US$89.3m
LFVN logo

LifeVantage

Symbol: NasdaqCM:LFVN
Market cap: US$81.6m
MIBE logo

Miami Breeze Car Care

Symbol: OTCPK:MIBE
Market cap: US$80.1m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide